title: Effects of varying the injection routes of PSK or OK-432 on development of immune responses against a superimposed antigen.
abstract: The present study examined functional and morphological modifications of development of immune responses to an unrelated antigenic stimulus by an ongoing response to a biological response modifier such as PSK or OK-432. Development of the immune responses was found to be strictly dependent upon the site where the ongoing response was occurring. In some cases, injection into the intraperitoneal site slightly augmented the development of a humoral immune response against a superimposed antigen, sheep erythrocytes, when the antigen had been injected into the site within 3 h after an injection of PSK. Thereafter, however, inhibition of the response was observed. Subcutaneous injection into the foot pad, but not into the upper chest, augmented the response. This augmentation occurred only when a superimposed antigen was injected into the site "prepared" with a previous injection of PSK, and showed a bell-shaped dependence on the dose of PSK. The foot pad site was also associated with an augmented development of a delayed type hypersensitivity against sheep erythrocytes when the antigen was injected into the "prepared" site. Morphological examination shows accumulation of inflammatory cells at the sites 2 to 7 days after an injection of PSK. The macrophages in the foot pad retained their "activated" state for at least 7 days after the injection whereas those in the peritoneal cavity were not sufficiently "activated" even after 2 days.
authors.affiliation: Department of Experimental Therapeutics, Kanazawa University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ryoyama
authors.forename: I
authors.initials: I
authors.lastname: Hori
authors.forename: C
authors.initials: C
authors.lastname: Ryoyama
authors.forename: T
authors.initials: T
authors.lastname: Umei
mesh_terms: D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D001688:Biological Products / Q000494:pharmacology*; D004912:Erythrocytes / Q000276:immunology; D005528:Foot / Q000473:pathology; D006968:Hypersensitivity, Delayed / Q000276:immunology / Q000473:pathology; D007114:Immunization; D007155:Immunologic Factors / Q000494:pharmacology*; D007700:Kinetics; D051379:Mice; D008810:Mice, Inbred C57BL; D010844:Picibanil / Q000494:pharmacology*; D011509:Proteoglycans / Q000494:pharmacology*; D012756:Sheep / Q000276:immunology
chemical_list: D001688:Biological Products; D007155:Immunologic Factors; D011509:Proteoglycans; D010844:Picibanil; C010770:polysaccharide-K